BioXcel Therapeutics Reports Q2 2024 Financial Results

August 6, 2024

DENVER, Colo., Aug 06, 2024 (247marketnews.com)- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) reported its second quarter of 2024 financial results

BioXcel’s CEO, Vimal Mehta, Ph.D., commented, “We are on track with our business priorities as we focus on bringing BXCL501 to the greatest number of patients in need.

“We are pleased with the progress with our SERENITY and TRANQUILITY programs and our focused market-access strategy for IGALMI™. Our confidence in our lead neuroscience asset is underpinned by its broad therapeutic potential across multiple neuropsychiatric conditions and its growing intellectual property portfolio.”

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.